I
131.87
0.00 (0.00%)
| 前收盘价格 | 131.87 |
| 收盘价格 | 131.90 |
| 平均成交量 (3个月) | 2,731,608 |
| 市值 | 14,047,055,872 |
| 预期市盈率 (P/E Forward) | 158.73 |
| 价格/销量 (P/S) | 19.89 |
| 股市价格/股市净资产 (P/B) | 12.15 |
| 52周波幅 | |
| 利润日期 | 5 May 2025 - 9 May 2025 |
| 营业毛利率 | -10.97% |
| 营业利益率 (TTM) | -14.65% |
| 稀释每股收益 (EPS TTM) | -0.720 |
| 季度收入增长率 (YOY) | 50.80% |
| 总债务/股东权益 (D/E MRQ) | 1.48% |
| 流动比率 (MRQ) | 6.36 |
| 营业现金流 (OCF TTM) | -73.18 M |
| 杠杆自由现金流 (LFCF TTM) | -63.55 M |
| 资产报酬率 (ROA TTM) | -6.96% |
| 股东权益报酬率 (ROE TTM) | -8.58% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 看跌 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 混合的 | |
| 股票 | Intra-Cellular Therapies Inc. | 混合的 | 看涨 |
AIStockmoo 评分
-1.5
| 分析师共识 | -0.5 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | -5.0 |
| 技术振荡指标 | 0.0 |
| 平均 | -1.50 |
|
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Growth |
| 内部持股比例 | 3.27% |
| 机构持股比例 | 96.54% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合